InnovAge Holding Corp. (INNV) Q4 2024 Earnings Call Transcript Summary
InnovAge Holding Corp. (INNV) Q4 2024 Earnings Call Transcript Summary
The following is a summary of the InnovAge Holding Corp. (INNV) Q4 2024 Earnings Call Transcript:
以下是Innovage Holding Corp.（INNV）2024年第四季度業績電話會議記錄的摘要：
Financial Performance:
財務業績：
InnovAge reported a Q4 revenue of approximately $199 million, showing a sequential improvement of 3.3% compared to the previous quarter.
Fiscal year 2024 total revenue stood at approximately $764 million, marking an 11% increase from fiscal year 2023.
Adjusted EBITDA for fiscal year 2024 was $16.5 million, reflecting an improvement of approximately $20 million from the negative $3.4 million in fiscal 2023.
Innovage報告第四季度收入約爲1.99億美元，與上一季度相比連續增長了3.3％。
2024財年的總收入約爲7.64億美元，比2023財年增長了11％。
2024財年調整後的息稅折舊攤銷前利潤爲1,650萬美元，較2023財年的負340萬美元增加了約2000萬美元。
Business Progress:
業務進展：
InnovAge expanded its operations by acquiring two California centers and opening two new centers in Florida.
A joint venture was executed with Orlando Health to foster growth.
InnovAge introduced numerous operational and clinical initiatives aimed at improving service quality and operational efficiency.
Innovage通過收購兩個加利福尼亞中心並在佛羅里達州開設兩個新中心來擴大其業務。
與奧蘭多健康公司成立了一家合資企業，以促進增長。
InnovAge推出了許多旨在提高服務質量和運營效率的運營和臨床舉措。
Opportunities:
機會：
InnovAge projects fiscal year 2025 revenue to range between $815 million to $865 million, with an adjusted EBITDA forecast of $24 million to $31 million, indicating expected growth in profitability.
The company anticipates growth and profitability from newer markets, including through initiatives and joint ventures, such as with Orlando Health.
Innovage預計，2025財年的收入將在8.15億美元至8.65億美元之間，調整後的息稅折舊攤銷前利潤預計爲2400萬美元至3,100萬美元，這表明盈利能力有望增長。
該公司預計，新市場將實現增長和盈利，包括通過計劃和合資企業，例如與奧蘭多健康的合資企業。
Risks:
風險：
InnovAge faces operational risks, including state delays in processing enrollments which could impact census growth projections.
De novo centers are expected to incur losses of $18 million to $20 million, influencing overall profitability.
InnovAge面臨運營風險，包括各州延遲辦理入學手續，這可能會影響人口普查的增長預測。
預計de novo中心將蒙受1,800萬至2000萬美元的損失，從而影響整體盈利能力。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。